OncoSec Medical Inc (ONCS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

24 N. MAIN STREET PENNINGTON, NJ 08534

OncoSec Medical Incorporated designs, develops, and commercializes novel cancer therapeutic products in the United States. Its products combine proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics, known as OMS ElectroOncology. The companys immunotherapy program uses the OncoSec Medical System to deliver engineered DNA plasmid constructs that encode a specific cytokine. It has three Phase II clinical trials underway with its OMS ElectroImmunotherapy product.

Data as of 2020-06-27
Market Cap46.294 Million Shares Outstanding23.032 Million Avg 30-day Volume292.166 Thousand
P/E Ratio Dividend Yield EPS-3.22
Price/Sales Price cash flow ratio Price free cash flow ratio-1.4
Book Value0.94 Price to Tangible Book2.1 Alpha-0.05
Short Interest Ratio % Short Interest to Float R-squared0.16709
BETA2.1316 52-week High/Low2.97 / 1.039 Stddev0.222468
View SEC Filings from ONCS instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 24 6 (0.39%)
Aggregate 13F shares on 03/31/2020: 777.559 Thousand 584.232 Thousand
Aggregate 13F shares on 12/31/2019: 726.193 Thousand 564.534 Thousand
Percent change: 7.07% 3.49%
Funds creating new positions: 4
Funds Adding to an existing position: 2 1
Funds closing out their position: 1 1
Funds reducing their position: 7 2
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ONCS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ONCS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MAYES, GREGORY T.

  • Director
0 2020-06-10 0

JENKINS ANNALISA

  • Director
0 2020-06-04 0

DEMESA JAMES M

  • Director
0 2020-05-29 1

O'CONNOR DANIEL J. CEO AND PRESIDENT

  • Officer
  • Director
109,095 2020-05-29 5

WARD ROBERT

  • Director
0 2020-05-29 1

KIM JOON

  • Director
0 2020-05-29 1

DALESANDRO MARGARET

  • Director
0 2020-05-29 1

DELAVERSANO ROBERT J PRINCIPAL ACCOUNTING OFFICER

  • Officer
16,683 2020-05-29 2

SMITH KEVIN RAYMOND MERRILL

  • Director
0 2020-05-29 2

ZHAO YUHANG

  • Director
0 2020-05-29 2

ZHOU CHAO

  • Director
0 2020-05-29 2

LYERLY HERBERT KIM

  • Director
0 2020-05-29 2

BONSTEIN SARA CHIEF FINANCIAL OFFICER

  • Officer
0 2020-05-12 3

MAIDA ANTHONY E III

198,668 2020-05-11 0

DHILLON AVTAR S

  • Director
62,052 2020-04-17 1

CHINA GRAND PHARMACEUTICAL & HEALTHCARE HOLDINGS LTD

SIRTEX MEDICAL US HOLDINGS, INC.

  • 10% Owner
  • SEE REMARKSSEE REMARKS
12,000,000 2020-02-07 2

CHINA GRAND PHARMACEUTICAL & HEALTHCARE HOLDINGS LTD

GRAND DECADE DEVELOPMENTS LTD

SIRTEX MEDICAL US HOLDINGS, INC.

  • 10% Owner
  • SEE REMARKSSEE REMARKSSEE REMARKS
12,000,000 2020-02-07 2

DHILLON PUNIT

  • Director
0 2019-12-20 0

ALPHA HOLDINGS, INC.

  • Director
  • 10% Owner
1,611,000 2019-07-17 2

SLANSKY RICHARD B CHIEF FINANCIAL OFFICER

  • Officer
270,016 2018-06-15 0

MOHAN-PETERSON SHEELA CHIEF LEGAL&COMPLIANCE OFFICER

  • Officer
9,520 2017-07-31 0

GARGOSKY SHARRON E CHIEF CLINICAL & REG. OFFICER

  • Officer
0 2017-03-29 0

PIERCE ROBERT HAMILTON CHIEF SCIENTIFIC OFFICER

  • Officer
0 2016-03-04 0

LE MAI HOPE CHIEF MEDICAL OFFICER

  • Officer
0 2015-08-20 0

VALLEJO VERONICA CHIEF FINANCIAL OFFICER

  • Officer
0 2015-03-03 0

CROSS MICHAEL CHIEF OPERATING OFFICER

  • Officer
1,214,000 2011-03-10 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

DEMESA JAMES M - Director

2020-05-29 A 37,500 a 37,500 0.00 direct

DELAVERSANO ROBERT J - Officer PRINCIPAL ACCOUNTING OFFICER

2020-05-29 A 25,362 a 25,362 16,683.00 direct

ZHAO YUHANG - Director

2020-05-29 A 25,000 a 25,000 0.00 direct

O'CONNOR DANIEL J. - Director - Officer CEO AND PRESIDENT

2020-05-29 A 304,000 a 304,000 109,095.00 direct

LYERLY HERBERT KIM - Director

2020-05-29 A 25,000 a 25,000 0.00 direct

DELAVERSANO ROBERT J - Officer PRINCIPAL ACCOUNTING OFFICER

2020-05-29 A 54,054 a 54,054 16,683.00 direct

ZHOU CHAO - Director

2020-05-29 A 25,000 a 25,000 0.00 direct

WARD ROBERT - Director

2020-05-29 A 25,000 a 25,000 0.00 direct

O'CONNOR DANIEL J. - Director - Officer CEO AND PRESIDENT

2020-05-29 F 44,471 $2.23 d 109,095 109,095.00 direct

KIM JOON - Director

2020-05-29 A 25,000 a 25,000 0.00 direct

DELAVERSANO ROBERT J - Officer PRINCIPAL ACCOUNTING OFFICER

2020-05-29 F 8,679 $2.23 d 16,683 16,683.00 direct

DALESANDRO MARGARET - Director

2020-05-29 A 37,500 a 37,500 0.00 direct

SMITH KEVIN RAYMOND MERRILL - Director

2020-05-29 A 25,000 a 25,000 0.00 direct

O'CONNOR DANIEL J. - Director - Officer CEO AND PRESIDENT

2020-05-29 A 90,580 a 153,566 109,095.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

**EXPERIMENTAL** Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin

Short Position History

Holder Net Short Position Position Date Origin
Squarepoint Ops LLC OncoSec Medical Inc 0.64% 2019-05-31 UK
Squarepoint Ops LLC OncoSec Medical Inc 0.54% 2019-05-30 UK
Squarepoint Ops LLC OncoSec Medical Inc 1.98% 2019-08-15 UK

Elevate your investments